Dicerna Pharmaceuticals Inc Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Held-to-maturity investments
Held-to-maturity investments, current
Restricted cash equivalents, current
Contract receivables
Withholding tax receivable
Prepaid expenses and other current assets
Deferred financing costs
Total current assets

NONCURRENT ASSETS:
Property and equipment, net
Right-of-use operating assets, net
Restricted cash equivalents, noncurrent
Held-to-maturity investments, noncurrent
Other noncurrent assets
Total noncurrent assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable
Accrued expenses and other current liabilities
Litigation settlement payable
Lease liability, current
Deferred revenue, current
Deferred income, current
Total current liabilities
NONCURRENT LIABILITIES:
Long-term payable and accrued interest
Deferred revenue, net of current portion
Lease liability, noncurrent
Deferred revenue, noncurrent
Deferred income, noncurrent
Derivative liability
Other noncurrent liabilities
Total noncurrent liabilities

TOTAL LIABILITIES
PREFERRED STOCK, $0.0001 par value and 5,000,000 shares authorized: Redeemable convertible preferred stock-740,126 and no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively (aggregate liquidation preference of $74,014 and $0 at September 30, 2017 and December 31, 2016, respectively) (Note 4)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value – 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2021 or December 31, 2020
Common stock, $0.0001 par value – 150,000,000 shares authorized; 77,834,693 and 75,757,213 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

Comments